Viridian Therapeutics, Inc. (VRDN): Capital Expenditures
$495.0K
Year ended 2025-12-31
$1.70M
Trailing 12 months to 2026-06-30
-14.7%
3-year compound annual growth
+63.8%
5-year compound annual growth
+14.9%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $495.0K | -3.1% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $511.0K | -43.1% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $898.0K | +12.7% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $797.0K | +135.8% | 2025-03-03, From 2022-01-01 |
| 2021-12-31 | $338.0K | +704.8% | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | $42.0K | -50.0% | 2022-03-11, From 2020-01-01 |
| 2019-12-31 | $84.0K | -81.1% | 2021-03-26, From 2019-01-01 |
| 2018-12-31 | $445.0K | +80.9% | 2020-03-13, From 2018-01-01 |
| 2017-12-31 | $246.0K | -1.6% | 2019-03-14, From 2017-01-01 |
| 2016-12-31 | $250.0K | +103.3% | 2018-03-15, From 2016-01-01 |
| 2015-12-31 | $123.0K | -53.8% | 2017-03-24, From 2015-01-01 |
| 2014-12-31 | $266.0K | n/m | 2016-03-21, From 2014-01-01 |
| 2013-12-31 | $5.0K | n/a | 2015-03-27, From 2013-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Viridian Therapeutics, Inc. (VRDN) | 2025-12-31 | $495.0K | -3.1% |
| Assembly Biosciences, Inc. (ASMB) | 2025-12-31 | $66.0K | +135.7% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $542.0K | -46.4% |
| Bicycle Therapeutics PLC (BCYC) | 2025-12-31 | $2.35M | +90.3% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $6.64M | n/m |
| AbCellera Biologics Inc. (ABCL) | 2025-12-31 | $42.77M | -45.4% |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | $220.0K | -29.0% |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | $12.90M | -28.1% |
| Fortress Biotech, Inc. (FBIO) | 2024-12-31 | $0 | -100.0% |
Compare VRDN, ASMB, RMTI, BCYC side by side · Screen every company in Pharmaceutical Preparations ↗